Paul Schimmel Net Worth

The estimated Net Worth of Paul Schimmel is at least $4.3 Milión dollars as of 10 May 2023. Paul Schimmel owns over 200,000 units of Atyr Pharma Inc stock worth over $594,744 and over the last 21 years he sold LIFE stock worth over $3,538,442. In addition, he makes $162,878 as Independent Director at Atyr Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Paul Schimmel LIFE stock SEC Form 4 insiders trading

Paul has made over 23 trades of the Atyr Pharma Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he bought 200,000 units of LIFE stock worth $450,000 on 10 May 2023.

The largest trade he's ever made was buying 254,000 units of Atyr Pharma Inc stock on 10 February 2020 worth over $1,079,500. On average, Paul trades about 19,924 units every 102 days since 2003. As of 10 May 2023 he still owns at least 313,023 units of Atyr Pharma Inc stock.

You can see the complete history of Paul Schimmel stock trades at the bottom of the page.

Paul Schimmel biography

Dr. Paul R. Schimmel Ph.D. serves as Independent Director of the Company. Dr. Schimmel is currently a director of Alnylam Pharmaceuticals, Inc. and Tocagen, Inc., both biopharmaceutical companies, as well as a director of several private companies. Dr. Schimmel is an Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute. He was formerly the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at the Massachusetts Institute of Technology. Dr. Schimmel holds a B.A. from Ohio Wesleyan University and a Ph.D. in biochemistry and biophysics from the Massachusetts Institute of Technology. He is an elected member of the American Academy of Arts and Sciences, the National Academy of Sciences, The National Academy of Medicine, The National Academy of Inventors, and the American Philosophical Society.

What is the salary of Paul Schimmel?

As the Independent Director of Atyr Pharma Inc, the total compensation of Paul Schimmel at Atyr Pharma Inc is $162,878. There are 6 executives at Atyr Pharma Inc getting paid more, with Dr. Sanjay S. Shukla having the highest compensation of $702,046.

How old is Paul Schimmel?

Paul Schimmel is 79, he's been the Independent Director of Atyr Pharma Inc since 2005. There are no older and 12 younger executives at Atyr Pharma Inc.

What's Paul Schimmel's mailing address?

Paul's mailing address filed with the SEC is C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO, CA, 92121.

Insiders trading at Atyr Pharma Inc

Over the last 16 years, insiders at Atyr Pharma Inc have traded over $27,288,922 worth of Atyr Pharma Inc stock and bought 966,653 units worth $5,761,237 . The most active insiders traders include James C Blair, Gregory T Lucier a Craig J Mundie. On average, Atyr Pharma Inc executives and independent directors trade stock every 22 days with the average trade being worth of $34,257. The most recent stock trade was executed by Jill Marie Broadfoot on 31 May 2024, trading 5,000 units of LIFE stock currently worth $8,950.

What does Atyr Pharma Inc do?

atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation

Complete history of Paul Schimmel stock trades at Alnylam Pharmaceuticals Inc, Atyr Pharma Inc, Repligen a Tocagen

Atyr Pharma Inc executives and stock owners

Atyr Pharma Inc executives and other stock owners filed with the SEC include:

• Dr. Sanjay S. Shukla,
  Pres, CEO & Director
• Sanjay Shukla,
  President, Chief Executive Officer, Director
• Jill M. Broadfoot,
  Chief Financial Officer
• Nancy E. Denyes Krueger,
  Gen. Counsel & Corp. Sec.
• Jill Broadfoot,
  Chief Financial Officer
• Nancy Denyes,
  General Counsel and Corporate Secretary
• Paul Schimmel,
  Independent Director
• John Clarke,
  Independent Chairman of the Board
• Svetlana Lucas,
  Independent Director
• Jeffrey Hatfield,
  Independent Director
• Jane Gross,
  Independent Director
• Timothy Coughlin,
  Independent Director
• Dr. David J. King,
  Scientific Consultant
• Dr. Melissa A. Ashlock,
  Sr. Advisor
• Dr. Ying J. Buechler,
  Exec. Director of Biologics Devel. & Manufacturing
• Peter Villiger,
  VP of Corp. Devel.
• Ashlee Dunston,
  Director of Investor Relations & Corp. Communications
• Xiang-Lei Yang Ph.D.,
  Founder
• Donald W Grimm,
  Director
• Arnold J Levine,
  Director
• Ronald Asbury Andrews,
  President, Medical Sciences
• George F Jr Adam,
  Director
• David C Uprichard,
  Director
• Gregory T Lucier,
  CEO
• Kelli Richard,
  Chief Accounting Officer
• Bradley G Lorimier,
  Director
• Peter Michael Leddy,
  SVP, Human Resources
• Balakrishnan S Iyer,
  Director
• Raymond V Dittamore,
  Director
• Per A Peterson,
  Director
• Craig J Mundie,
  Director
• Mark P Stevenson,
  President & COO
• Ora H. Pescovitz,
  Director
• Ronald A Matricaria,
  Director
• John A Cottingham,
  Chief Legal Officer
• David F Hoffmeister,
  Chief Financial Officer
• Claude Benchimol,
  SVP, Advanced Genomic Systems
• William H Longfield,
  Director
• Nicolas Barthelemy,
  President, Cell Systems
• John L Miller,
  President - Genetic Systems
• Mark Sean O'donnell,
  SVP, Global Operations & Serv.
• Peter Dansky,
  Pres, Molecular Biology Sys
• Bernd Brust,
  Pres, Commercial Operations
• Paul David Grossman,
  SVP, Corporate Strategy & Dev.
• W Ann Reynolds,
  Director
• Joseph C Beery,
  SVP, Chief Information Officer
• William S Shanahan,
  Director
• James C Blair,
  Director
• John Mendlein,
  Director
• Sara Zaknoen,